Global Pegfilgrastim Biosimilar Market
Global Pegfilgrastim Biosimilar Market

Pegfilgrastim Biosimilar Comprehensive Study by Type (Ristempa, Tezmota, Fulphila, Pelgraz, Udenyca), Application (Chemotherapy Induced Neutropenia, Transplantation, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Form (Oral Suspension, Tablets, Injections) Players and Region - Global Market Outlook to 2026

Pegfilgrastim Biosimilar Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 243 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Pegfilgrastim Biosimilar Market?

Pegfilgrastim is a long-acting version of filgrastim (Neupogen) that is indicated for selected cancer patients who are undergoing chemotherapy to increase the production of anti-infection white blood cells. The indication is specific to those receiving myelosuppressive anticancer drugs that are associated with a clinically significant incidence of febrile neutropenia. The market for pegfilgrastim biosimilars consists of the sale of pegfilgrastim biosimilar drugs and related services. The drugs are used during the course of cancer treatment to reduce the risk of infection for patients undergoing immunosuppressive treatments such as chemotherapy. The drug has other uses that involve protecting against infections where the immune system is weakened, such as bone marrow transplants. Biosimilars are biological products that are manufactured in such a way that they are identical to an already approved biological called the reference medicine. Biosimilars should demonstrate similar safety and efficacy compared to the reference biological product. Pegfilgrastim is a PEGylated form of the filgrastim analog of recombinant human granulocyte colony-stimulating factor (G-CSF).

The market study is being classified by Type (Ristempa, Tezmota, Fulphila, Pelgraz and Udenyca), by Application (Chemotherapy Induced Neutropenia, Transplantation and Others) and major geographies with country level break-up.

Coherus Biosciences Inc. (United States), Biocon (India), Mylan (United States), Pfizer (United States), Sandoz (Novartis) (Germany), USV Biologics (India), Apotex Pty Ltd (Australia), Stada Arzneimittel (Germany), Kyowa Kirin Co., Ltd. (Japan), Qilu Pharmaceutical (China) and Gennova Biopharmaceuticals Limited (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Lupin Limited (India), Dr. Reddy’s Laboratories Ltd. (India), Fresenius Kabi (Germany) and Napp Pharmaceuticals (United Kingdom).

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that European Players will contribute to the maximum growth of Global Pegfilgrastim Biosimilar market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Pegfilgrastim Biosimilar market by Type, Application and Region.

On the basis of geography, the market of Pegfilgrastim Biosimilar has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • An Increased Prevalence of Cancer
  • Low Costs of Biosimilars
  • Increased Adoption of the Biosimilars

Market Trend
  • Increase In Healthcare Access and Rising Prevalence of Chronic Diseases
  • Revised FDA Regulations to Facilitate Biosimilar Drug Development

Restraints
  • Stringent Regulations Related To Biosimilar Approvals and Prolonged Production

Opportunities
  • Increase in Healthcare Expenditure
  • Increase in Pharmaceutical R&D Expenditure

Challenges
  • Side Effects associated With the Drugs


In October 2018, Sandoz, which is a Novartis biosimilars division, had received FDA approval for its biosimilar HyrimozTM (adalimumab-adaz) for the treatment of rheumatoid arthritis as well as juvenile idiopathic arthritis in patients four years and older.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Pegfilgrastim Biosimilar, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Ristempa
  • Tezmota
  • Fulphila
  • Pelgraz
  • Udenyca
By Application
  • Chemotherapy Induced Neutropenia
  • Transplantation
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Form
  • Oral Suspension
  • Tablets
  • Injections

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. An Increased Prevalence of Cancer
      • 3.2.2. Low Costs of Biosimilars
      • 3.2.3. Increased Adoption of the Biosimilars
    • 3.3. Market Challenges
      • 3.3.1. Side Effects associated With the Drugs
    • 3.4. Market Trends
      • 3.4.1. Increase In Healthcare Access and Rising Prevalence of Chronic Diseases
      • 3.4.2. Revised FDA Regulations to Facilitate Biosimilar Drug Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pegfilgrastim Biosimilar, by Type, Application, Distribution Channel, Form and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Pegfilgrastim Biosimilar (Value)
      • 5.2.1. Global Pegfilgrastim Biosimilar by: Type (Value)
        • 5.2.1.1. Ristempa
        • 5.2.1.2. Tezmota
        • 5.2.1.3. Fulphila
        • 5.2.1.4. Pelgraz
        • 5.2.1.5. Udenyca
      • 5.2.2. Global Pegfilgrastim Biosimilar by: Application (Value)
        • 5.2.2.1. Chemotherapy Induced Neutropenia
        • 5.2.2.2. Transplantation
        • 5.2.2.3. Others
      • 5.2.3. Global Pegfilgrastim Biosimilar by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Pegfilgrastim Biosimilar by: Form (Value)
        • 5.2.4.1. Oral Suspension
        • 5.2.4.2. Tablets
        • 5.2.4.3. Injections
      • 5.2.5. Global Pegfilgrastim Biosimilar Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Pegfilgrastim Biosimilar (Volume)
      • 5.3.1. Global Pegfilgrastim Biosimilar by: Type (Volume)
        • 5.3.1.1. Ristempa
        • 5.3.1.2. Tezmota
        • 5.3.1.3. Fulphila
        • 5.3.1.4. Pelgraz
        • 5.3.1.5. Udenyca
      • 5.3.2. Global Pegfilgrastim Biosimilar by: Application (Volume)
        • 5.3.2.1. Chemotherapy Induced Neutropenia
        • 5.3.2.2. Transplantation
        • 5.3.2.3. Others
      • 5.3.3. Global Pegfilgrastim Biosimilar by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacies
        • 5.3.3.2. Retail Pharmacies
        • 5.3.3.3. Online Pharmacies
      • 5.3.4. Global Pegfilgrastim Biosimilar by: Form (Volume)
        • 5.3.4.1. Oral Suspension
        • 5.3.4.2. Tablets
        • 5.3.4.3. Injections
      • 5.3.5. Global Pegfilgrastim Biosimilar Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Pegfilgrastim Biosimilar (Price)
      • 5.4.1. Global Pegfilgrastim Biosimilar by: Type (Price)
  • 6. Pegfilgrastim Biosimilar: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Coherus Biosciences Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Biocon (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mylan (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sandoz (Novartis) (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. USV Biologics (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Apotex Pty Ltd (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Stada Arzneimittel (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Kyowa Kirin Co., Ltd. (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Qilu Pharmaceutical (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Gennova Biopharmaceuticals Limited (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Pegfilgrastim Biosimilar Sale, by Type, Application, Distribution Channel, Form and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Pegfilgrastim Biosimilar (Value)
      • 7.2.1. Global Pegfilgrastim Biosimilar by: Type (Value)
        • 7.2.1.1. Ristempa
        • 7.2.1.2. Tezmota
        • 7.2.1.3. Fulphila
        • 7.2.1.4. Pelgraz
        • 7.2.1.5. Udenyca
      • 7.2.2. Global Pegfilgrastim Biosimilar by: Application (Value)
        • 7.2.2.1. Chemotherapy Induced Neutropenia
        • 7.2.2.2. Transplantation
        • 7.2.2.3. Others
      • 7.2.3. Global Pegfilgrastim Biosimilar by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Pegfilgrastim Biosimilar by: Form (Value)
        • 7.2.4.1. Oral Suspension
        • 7.2.4.2. Tablets
        • 7.2.4.3. Injections
      • 7.2.5. Global Pegfilgrastim Biosimilar Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Pegfilgrastim Biosimilar (Volume)
      • 7.3.1. Global Pegfilgrastim Biosimilar by: Type (Volume)
        • 7.3.1.1. Ristempa
        • 7.3.1.2. Tezmota
        • 7.3.1.3. Fulphila
        • 7.3.1.4. Pelgraz
        • 7.3.1.5. Udenyca
      • 7.3.2. Global Pegfilgrastim Biosimilar by: Application (Volume)
        • 7.3.2.1. Chemotherapy Induced Neutropenia
        • 7.3.2.2. Transplantation
        • 7.3.2.3. Others
      • 7.3.3. Global Pegfilgrastim Biosimilar by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacies
        • 7.3.3.2. Retail Pharmacies
        • 7.3.3.3. Online Pharmacies
      • 7.3.4. Global Pegfilgrastim Biosimilar by: Form (Volume)
        • 7.3.4.1. Oral Suspension
        • 7.3.4.2. Tablets
        • 7.3.4.3. Injections
      • 7.3.5. Global Pegfilgrastim Biosimilar Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Pegfilgrastim Biosimilar (Price)
      • 7.4.1. Global Pegfilgrastim Biosimilar by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pegfilgrastim Biosimilar: by Type(USD Million)
  • Table 2. Pegfilgrastim Biosimilar Ristempa , by Region USD Million (2015-2020)
  • Table 3. Pegfilgrastim Biosimilar Tezmota , by Region USD Million (2015-2020)
  • Table 4. Pegfilgrastim Biosimilar Fulphila , by Region USD Million (2015-2020)
  • Table 5. Pegfilgrastim Biosimilar Pelgraz , by Region USD Million (2015-2020)
  • Table 6. Pegfilgrastim Biosimilar Udenyca , by Region USD Million (2015-2020)
  • Table 7. Pegfilgrastim Biosimilar: by Application(USD Million)
  • Table 8. Pegfilgrastim Biosimilar Chemotherapy Induced Neutropenia , by Region USD Million (2015-2020)
  • Table 9. Pegfilgrastim Biosimilar Transplantation , by Region USD Million (2015-2020)
  • Table 10. Pegfilgrastim Biosimilar Others , by Region USD Million (2015-2020)
  • Table 11. Pegfilgrastim Biosimilar: by Distribution Channel(USD Million)
  • Table 12. Pegfilgrastim Biosimilar Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 13. Pegfilgrastim Biosimilar Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 14. Pegfilgrastim Biosimilar Online Pharmacies , by Region USD Million (2015-2020)
  • Table 15. Pegfilgrastim Biosimilar: by Form(USD Million)
  • Table 16. Pegfilgrastim Biosimilar Oral Suspension , by Region USD Million (2015-2020)
  • Table 17. Pegfilgrastim Biosimilar Tablets , by Region USD Million (2015-2020)
  • Table 18. Pegfilgrastim Biosimilar Injections , by Region USD Million (2015-2020)
  • Table 19. South America Pegfilgrastim Biosimilar, by Country USD Million (2015-2020)
  • Table 20. South America Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 21. South America Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 22. South America Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 23. South America Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 24. Brazil Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 25. Brazil Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 26. Brazil Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 27. Brazil Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 28. Argentina Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 29. Argentina Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 30. Argentina Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 31. Argentina Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 32. Rest of South America Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 33. Rest of South America Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 34. Rest of South America Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 35. Rest of South America Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 36. Asia Pacific Pegfilgrastim Biosimilar, by Country USD Million (2015-2020)
  • Table 37. Asia Pacific Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 38. Asia Pacific Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 39. Asia Pacific Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 40. Asia Pacific Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 41. China Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 42. China Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 43. China Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 44. China Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 45. Japan Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 46. Japan Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 47. Japan Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 48. Japan Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 49. India Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 50. India Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 51. India Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 52. India Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 53. South Korea Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 54. South Korea Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 55. South Korea Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 56. South Korea Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 57. Taiwan Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 58. Taiwan Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 59. Taiwan Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 60. Taiwan Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 61. Australia Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 62. Australia Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 63. Australia Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 64. Australia Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 69. Europe Pegfilgrastim Biosimilar, by Country USD Million (2015-2020)
  • Table 70. Europe Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 71. Europe Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 72. Europe Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 73. Europe Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 74. Germany Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 75. Germany Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 76. Germany Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 77. Germany Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 78. France Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 79. France Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 80. France Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 81. France Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 82. Italy Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 83. Italy Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 84. Italy Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 85. Italy Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 86. United Kingdom Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 87. United Kingdom Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 88. United Kingdom Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 89. United Kingdom Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 90. Netherlands Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 91. Netherlands Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 92. Netherlands Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 93. Netherlands Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 94. Rest of Europe Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 95. Rest of Europe Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 96. Rest of Europe Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 97. Rest of Europe Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 98. MEA Pegfilgrastim Biosimilar, by Country USD Million (2015-2020)
  • Table 99. MEA Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 100. MEA Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 101. MEA Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 102. MEA Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 103. Middle East Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 104. Middle East Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 105. Middle East Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 106. Middle East Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 107. Africa Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 108. Africa Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 109. Africa Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 110. Africa Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 111. North America Pegfilgrastim Biosimilar, by Country USD Million (2015-2020)
  • Table 112. North America Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 113. North America Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 114. North America Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 115. North America Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 116. United States Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 117. United States Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 118. United States Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 119. United States Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 120. Canada Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 121. Canada Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 122. Canada Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 123. Canada Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 124. Mexico Pegfilgrastim Biosimilar, by Type USD Million (2015-2020)
  • Table 125. Mexico Pegfilgrastim Biosimilar, by Application USD Million (2015-2020)
  • Table 126. Mexico Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2015-2020)
  • Table 127. Mexico Pegfilgrastim Biosimilar, by Form USD Million (2015-2020)
  • Table 128. Pegfilgrastim Biosimilar Sales: by Type(K Tons)
  • Table 129. Pegfilgrastim Biosimilar Sales Ristempa , by Region K Tons (2015-2020)
  • Table 130. Pegfilgrastim Biosimilar Sales Tezmota , by Region K Tons (2015-2020)
  • Table 131. Pegfilgrastim Biosimilar Sales Fulphila , by Region K Tons (2015-2020)
  • Table 132. Pegfilgrastim Biosimilar Sales Pelgraz , by Region K Tons (2015-2020)
  • Table 133. Pegfilgrastim Biosimilar Sales Udenyca , by Region K Tons (2015-2020)
  • Table 134. Pegfilgrastim Biosimilar Sales: by Application(K Tons)
  • Table 135. Pegfilgrastim Biosimilar Sales Chemotherapy Induced Neutropenia , by Region K Tons (2015-2020)
  • Table 136. Pegfilgrastim Biosimilar Sales Transplantation , by Region K Tons (2015-2020)
  • Table 137. Pegfilgrastim Biosimilar Sales Others , by Region K Tons (2015-2020)
  • Table 138. Pegfilgrastim Biosimilar Sales: by Distribution Channel(K Tons)
  • Table 139. Pegfilgrastim Biosimilar Sales Hospital Pharmacies , by Region K Tons (2015-2020)
  • Table 140. Pegfilgrastim Biosimilar Sales Retail Pharmacies , by Region K Tons (2015-2020)
  • Table 141. Pegfilgrastim Biosimilar Sales Online Pharmacies , by Region K Tons (2015-2020)
  • Table 142. Pegfilgrastim Biosimilar Sales: by Form(K Tons)
  • Table 143. Pegfilgrastim Biosimilar Sales Oral Suspension , by Region K Tons (2015-2020)
  • Table 144. Pegfilgrastim Biosimilar Sales Tablets , by Region K Tons (2015-2020)
  • Table 145. Pegfilgrastim Biosimilar Sales Injections , by Region K Tons (2015-2020)
  • Table 146. South America Pegfilgrastim Biosimilar Sales, by Country K Tons (2015-2020)
  • Table 147. South America Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 148. South America Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 149. South America Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 150. South America Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 151. Brazil Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 152. Brazil Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 153. Brazil Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 154. Brazil Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 155. Argentina Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 156. Argentina Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 157. Argentina Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 158. Argentina Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 159. Rest of South America Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 160. Rest of South America Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 161. Rest of South America Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 162. Rest of South America Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 163. Asia Pacific Pegfilgrastim Biosimilar Sales, by Country K Tons (2015-2020)
  • Table 164. Asia Pacific Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 165. Asia Pacific Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 166. Asia Pacific Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 167. Asia Pacific Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 168. China Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 169. China Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 170. China Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 171. China Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 172. Japan Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 173. Japan Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 174. Japan Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 175. Japan Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 176. India Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 177. India Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 178. India Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 179. India Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 180. South Korea Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 181. South Korea Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 182. South Korea Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 183. South Korea Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 184. Taiwan Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 185. Taiwan Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 186. Taiwan Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 187. Taiwan Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 188. Australia Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 189. Australia Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 190. Australia Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 191. Australia Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 192. Rest of Asia-Pacific Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 193. Rest of Asia-Pacific Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 194. Rest of Asia-Pacific Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 195. Rest of Asia-Pacific Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 196. Europe Pegfilgrastim Biosimilar Sales, by Country K Tons (2015-2020)
  • Table 197. Europe Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 198. Europe Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 199. Europe Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 200. Europe Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 201. Germany Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 202. Germany Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 203. Germany Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 204. Germany Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 205. France Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 206. France Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 207. France Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 208. France Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 209. Italy Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 210. Italy Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 211. Italy Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 212. Italy Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 213. United Kingdom Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 214. United Kingdom Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 215. United Kingdom Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 216. United Kingdom Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 217. Netherlands Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 218. Netherlands Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 219. Netherlands Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 220. Netherlands Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 221. Rest of Europe Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 222. Rest of Europe Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 223. Rest of Europe Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 224. Rest of Europe Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 225. MEA Pegfilgrastim Biosimilar Sales, by Country K Tons (2015-2020)
  • Table 226. MEA Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 227. MEA Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 228. MEA Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 229. MEA Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 230. Middle East Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 231. Middle East Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 232. Middle East Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 233. Middle East Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 234. Africa Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 235. Africa Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 236. Africa Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 237. Africa Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 238. North America Pegfilgrastim Biosimilar Sales, by Country K Tons (2015-2020)
  • Table 239. North America Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 240. North America Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 241. North America Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 242. North America Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 243. United States Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 244. United States Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 245. United States Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 246. United States Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 247. Canada Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 248. Canada Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 249. Canada Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 250. Canada Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 251. Mexico Pegfilgrastim Biosimilar Sales, by Type K Tons (2015-2020)
  • Table 252. Mexico Pegfilgrastim Biosimilar Sales, by Application K Tons (2015-2020)
  • Table 253. Mexico Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2015-2020)
  • Table 254. Mexico Pegfilgrastim Biosimilar Sales, by Form K Tons (2015-2020)
  • Table 255. Pegfilgrastim Biosimilar: by Type(USD/Units)
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Pegfilgrastim Biosimilar: by Type(USD Million)
  • Table 268. Pegfilgrastim Biosimilar Ristempa , by Region USD Million (2021-2026)
  • Table 269. Pegfilgrastim Biosimilar Tezmota , by Region USD Million (2021-2026)
  • Table 270. Pegfilgrastim Biosimilar Fulphila , by Region USD Million (2021-2026)
  • Table 271. Pegfilgrastim Biosimilar Pelgraz , by Region USD Million (2021-2026)
  • Table 272. Pegfilgrastim Biosimilar Udenyca , by Region USD Million (2021-2026)
  • Table 273. Pegfilgrastim Biosimilar: by Application(USD Million)
  • Table 274. Pegfilgrastim Biosimilar Chemotherapy Induced Neutropenia , by Region USD Million (2021-2026)
  • Table 275. Pegfilgrastim Biosimilar Transplantation , by Region USD Million (2021-2026)
  • Table 276. Pegfilgrastim Biosimilar Others , by Region USD Million (2021-2026)
  • Table 277. Pegfilgrastim Biosimilar: by Distribution Channel(USD Million)
  • Table 278. Pegfilgrastim Biosimilar Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 279. Pegfilgrastim Biosimilar Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 280. Pegfilgrastim Biosimilar Online Pharmacies , by Region USD Million (2021-2026)
  • Table 281. Pegfilgrastim Biosimilar: by Form(USD Million)
  • Table 282. Pegfilgrastim Biosimilar Oral Suspension , by Region USD Million (2021-2026)
  • Table 283. Pegfilgrastim Biosimilar Tablets , by Region USD Million (2021-2026)
  • Table 284. Pegfilgrastim Biosimilar Injections , by Region USD Million (2021-2026)
  • Table 285. South America Pegfilgrastim Biosimilar, by Country USD Million (2021-2026)
  • Table 286. South America Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 287. South America Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 288. South America Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 289. South America Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 290. Brazil Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 291. Brazil Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 292. Brazil Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 293. Brazil Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 294. Argentina Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 295. Argentina Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 296. Argentina Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 297. Argentina Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 298. Rest of South America Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 299. Rest of South America Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 300. Rest of South America Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 301. Rest of South America Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 302. Asia Pacific Pegfilgrastim Biosimilar, by Country USD Million (2021-2026)
  • Table 303. Asia Pacific Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 304. Asia Pacific Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 305. Asia Pacific Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 306. Asia Pacific Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 307. China Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 308. China Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 309. China Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 310. China Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 311. Japan Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 312. Japan Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 313. Japan Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 314. Japan Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 315. India Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 316. India Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 317. India Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 318. India Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 319. South Korea Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 320. South Korea Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 321. South Korea Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 322. South Korea Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 323. Taiwan Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 324. Taiwan Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 325. Taiwan Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 326. Taiwan Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 327. Australia Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 328. Australia Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 329. Australia Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 330. Australia Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 331. Rest of Asia-Pacific Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 332. Rest of Asia-Pacific Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 333. Rest of Asia-Pacific Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 334. Rest of Asia-Pacific Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 335. Europe Pegfilgrastim Biosimilar, by Country USD Million (2021-2026)
  • Table 336. Europe Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 337. Europe Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 338. Europe Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 339. Europe Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 340. Germany Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 341. Germany Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 342. Germany Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 343. Germany Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 344. France Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 345. France Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 346. France Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 347. France Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 348. Italy Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 349. Italy Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 350. Italy Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 351. Italy Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 352. United Kingdom Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 353. United Kingdom Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 354. United Kingdom Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 355. United Kingdom Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 356. Netherlands Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 357. Netherlands Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 358. Netherlands Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 359. Netherlands Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 360. Rest of Europe Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 361. Rest of Europe Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 362. Rest of Europe Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 363. Rest of Europe Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 364. MEA Pegfilgrastim Biosimilar, by Country USD Million (2021-2026)
  • Table 365. MEA Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 366. MEA Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 367. MEA Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 368. MEA Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 369. Middle East Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 370. Middle East Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 371. Middle East Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 372. Middle East Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 373. Africa Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 374. Africa Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 375. Africa Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 376. Africa Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 377. North America Pegfilgrastim Biosimilar, by Country USD Million (2021-2026)
  • Table 378. North America Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 379. North America Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 380. North America Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 381. North America Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 382. United States Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 383. United States Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 384. United States Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 385. United States Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 386. Canada Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 387. Canada Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 388. Canada Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 389. Canada Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 390. Mexico Pegfilgrastim Biosimilar, by Type USD Million (2021-2026)
  • Table 391. Mexico Pegfilgrastim Biosimilar, by Application USD Million (2021-2026)
  • Table 392. Mexico Pegfilgrastim Biosimilar, by Distribution Channel USD Million (2021-2026)
  • Table 393. Mexico Pegfilgrastim Biosimilar, by Form USD Million (2021-2026)
  • Table 394. Pegfilgrastim Biosimilar Sales: by Type(K Tons)
  • Table 395. Pegfilgrastim Biosimilar Sales Ristempa , by Region K Tons (2021-2026)
  • Table 396. Pegfilgrastim Biosimilar Sales Tezmota , by Region K Tons (2021-2026)
  • Table 397. Pegfilgrastim Biosimilar Sales Fulphila , by Region K Tons (2021-2026)
  • Table 398. Pegfilgrastim Biosimilar Sales Pelgraz , by Region K Tons (2021-2026)
  • Table 399. Pegfilgrastim Biosimilar Sales Udenyca , by Region K Tons (2021-2026)
  • Table 400. Pegfilgrastim Biosimilar Sales: by Application(K Tons)
  • Table 401. Pegfilgrastim Biosimilar Sales Chemotherapy Induced Neutropenia , by Region K Tons (2021-2026)
  • Table 402. Pegfilgrastim Biosimilar Sales Transplantation , by Region K Tons (2021-2026)
  • Table 403. Pegfilgrastim Biosimilar Sales Others , by Region K Tons (2021-2026)
  • Table 404. Pegfilgrastim Biosimilar Sales: by Distribution Channel(K Tons)
  • Table 405. Pegfilgrastim Biosimilar Sales Hospital Pharmacies , by Region K Tons (2021-2026)
  • Table 406. Pegfilgrastim Biosimilar Sales Retail Pharmacies , by Region K Tons (2021-2026)
  • Table 407. Pegfilgrastim Biosimilar Sales Online Pharmacies , by Region K Tons (2021-2026)
  • Table 408. Pegfilgrastim Biosimilar Sales: by Form(K Tons)
  • Table 409. Pegfilgrastim Biosimilar Sales Oral Suspension , by Region K Tons (2021-2026)
  • Table 410. Pegfilgrastim Biosimilar Sales Tablets , by Region K Tons (2021-2026)
  • Table 411. Pegfilgrastim Biosimilar Sales Injections , by Region K Tons (2021-2026)
  • Table 412. South America Pegfilgrastim Biosimilar Sales, by Country K Tons (2021-2026)
  • Table 413. South America Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 414. South America Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 415. South America Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 416. South America Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 417. Brazil Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 418. Brazil Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 419. Brazil Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 420. Brazil Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 421. Argentina Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 422. Argentina Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 423. Argentina Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 424. Argentina Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 425. Rest of South America Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 426. Rest of South America Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 427. Rest of South America Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 428. Rest of South America Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 429. Asia Pacific Pegfilgrastim Biosimilar Sales, by Country K Tons (2021-2026)
  • Table 430. Asia Pacific Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 431. Asia Pacific Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 432. Asia Pacific Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 433. Asia Pacific Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 434. China Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 435. China Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 436. China Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 437. China Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 438. Japan Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 439. Japan Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 440. Japan Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 441. Japan Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 442. India Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 443. India Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 444. India Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 445. India Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 446. South Korea Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 447. South Korea Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 448. South Korea Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 449. South Korea Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 450. Taiwan Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 451. Taiwan Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 452. Taiwan Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 453. Taiwan Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 454. Australia Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 455. Australia Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 456. Australia Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 457. Australia Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 458. Rest of Asia-Pacific Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 459. Rest of Asia-Pacific Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 460. Rest of Asia-Pacific Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 461. Rest of Asia-Pacific Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 462. Europe Pegfilgrastim Biosimilar Sales, by Country K Tons (2021-2026)
  • Table 463. Europe Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 464. Europe Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 465. Europe Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 466. Europe Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 467. Germany Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 468. Germany Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 469. Germany Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 470. Germany Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 471. France Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 472. France Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 473. France Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 474. France Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 475. Italy Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 476. Italy Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 477. Italy Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 478. Italy Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 479. United Kingdom Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 480. United Kingdom Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 481. United Kingdom Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 482. United Kingdom Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 483. Netherlands Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 484. Netherlands Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 485. Netherlands Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 486. Netherlands Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 487. Rest of Europe Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 488. Rest of Europe Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 489. Rest of Europe Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 490. Rest of Europe Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 491. MEA Pegfilgrastim Biosimilar Sales, by Country K Tons (2021-2026)
  • Table 492. MEA Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 493. MEA Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 494. MEA Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 495. MEA Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 496. Middle East Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 497. Middle East Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 498. Middle East Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 499. Middle East Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 500. Africa Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 501. Africa Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 502. Africa Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 503. Africa Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 504. North America Pegfilgrastim Biosimilar Sales, by Country K Tons (2021-2026)
  • Table 505. North America Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 506. North America Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 507. North America Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 508. North America Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 509. United States Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 510. United States Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 511. United States Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 512. United States Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 513. Canada Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 514. Canada Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 515. Canada Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 516. Canada Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 517. Mexico Pegfilgrastim Biosimilar Sales, by Type K Tons (2021-2026)
  • Table 518. Mexico Pegfilgrastim Biosimilar Sales, by Application K Tons (2021-2026)
  • Table 519. Mexico Pegfilgrastim Biosimilar Sales, by Distribution Channel K Tons (2021-2026)
  • Table 520. Mexico Pegfilgrastim Biosimilar Sales, by Form K Tons (2021-2026)
  • Table 521. Pegfilgrastim Biosimilar: by Type(USD/Units)
  • Table 522. Research Programs/Design for This Report
  • Table 523. Key Data Information from Secondary Sources
  • Table 524. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pegfilgrastim Biosimilar: by Type USD Million (2015-2020)
  • Figure 5. Global Pegfilgrastim Biosimilar: by Application USD Million (2015-2020)
  • Figure 6. Global Pegfilgrastim Biosimilar: by Distribution Channel USD Million (2015-2020)
  • Figure 7. Global Pegfilgrastim Biosimilar: by Form USD Million (2015-2020)
  • Figure 8. South America Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 9. Asia Pacific Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 10. Europe Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 11. MEA Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 12. North America Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 13. Global Pegfilgrastim Biosimilar: by Type K Tons (2015-2020)
  • Figure 14. Global Pegfilgrastim Biosimilar: by Application K Tons (2015-2020)
  • Figure 15. Global Pegfilgrastim Biosimilar: by Distribution Channel K Tons (2015-2020)
  • Figure 16. Global Pegfilgrastim Biosimilar: by Form K Tons (2015-2020)
  • Figure 17. South America Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 18. Asia Pacific Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 19. Europe Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 20. MEA Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 21. North America Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 22. Global Pegfilgrastim Biosimilar: by Type USD/Units (2015-2020)
  • Figure 23. Global Pegfilgrastim Biosimilar share by Players 2020 (%)
  • Figure 24. Global Pegfilgrastim Biosimilar share by Players (Top 3) 2020(%)
  • Figure 25. Global Pegfilgrastim Biosimilar share by Players (Top 5) 2020(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Coherus Biosciences Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Coherus Biosciences Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Biocon (India) Revenue, Net Income and Gross profit
  • Figure 30. Biocon (India) Revenue: by Geography 2020
  • Figure 31. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 32. Mylan (United States) Revenue: by Geography 2020
  • Figure 33. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer (United States) Revenue: by Geography 2020
  • Figure 35. Sandoz (Novartis) (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Sandoz (Novartis) (Germany) Revenue: by Geography 2020
  • Figure 37. USV Biologics (India) Revenue, Net Income and Gross profit
  • Figure 38. USV Biologics (India) Revenue: by Geography 2020
  • Figure 39. Apotex Pty Ltd (Australia) Revenue, Net Income and Gross profit
  • Figure 40. Apotex Pty Ltd (Australia) Revenue: by Geography 2020
  • Figure 41. Stada Arzneimittel (Germany) Revenue, Net Income and Gross profit
  • Figure 42. Stada Arzneimittel (Germany) Revenue: by Geography 2020
  • Figure 43. Kyowa Kirin Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 44. Kyowa Kirin Co., Ltd. (Japan) Revenue: by Geography 2020
  • Figure 45. Qilu Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 46. Qilu Pharmaceutical (China) Revenue: by Geography 2020
  • Figure 47. Gennova Biopharmaceuticals Limited (India) Revenue, Net Income and Gross profit
  • Figure 48. Gennova Biopharmaceuticals Limited (India) Revenue: by Geography 2020
  • Figure 49. Global Pegfilgrastim Biosimilar: by Type USD Million (2021-2026)
  • Figure 50. Global Pegfilgrastim Biosimilar: by Application USD Million (2021-2026)
  • Figure 51. Global Pegfilgrastim Biosimilar: by Distribution Channel USD Million (2021-2026)
  • Figure 52. Global Pegfilgrastim Biosimilar: by Form USD Million (2021-2026)
  • Figure 53. South America Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 54. Asia Pacific Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 55. Europe Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 56. MEA Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 57. North America Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 58. Global Pegfilgrastim Biosimilar: by Type K Tons (2021-2026)
  • Figure 59. Global Pegfilgrastim Biosimilar: by Application K Tons (2021-2026)
  • Figure 60. Global Pegfilgrastim Biosimilar: by Distribution Channel K Tons (2021-2026)
  • Figure 61. Global Pegfilgrastim Biosimilar: by Form K Tons (2021-2026)
  • Figure 62. South America Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 63. Asia Pacific Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 64. Europe Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 65. MEA Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 66. North America Pegfilgrastim Biosimilar Share (%), by Country
  • Figure 67. Global Pegfilgrastim Biosimilar: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Coherus Biosciences Inc. (United States)
  • Biocon (India)
  • Mylan (United States)
  • Pfizer (United States)
  • Sandoz (Novartis) (Germany)
  • USV Biologics (India)
  • Apotex Pty Ltd (Australia)
  • Stada Arzneimittel (Germany)
  • Kyowa Kirin Co., Ltd. (Japan)
  • Qilu Pharmaceutical (China)
  • Gennova Biopharmaceuticals Limited (India)
Additional players considered in the study are as follows:
Lupin Limited (India) , Dr. Reddy’s Laboratories Ltd. (India) , Fresenius Kabi (Germany) , Napp Pharmaceuticals (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation